PDUFA Negotiations: REMS Mud-Slinging, Supply Chain Compromising, GAIN Diminishing?
PhRMA and GPhA exchange unpleasantries over the legislative pay-for; FDA offers a compromise track-and-trace program that would use the industry proposal as a starting point; structure of antibiotic incentives still unresolved.
You may also be interested in...
Brand drug representative tells Senate subcommittee there are problems with bill that would make it easier for generics to obtain samples, but did not appear interested in scrapping it.
Senate bill would allow generic companies to bring civil suits against brand sponsors that use REMS requirements to avoid providing samples for testing.
Citing the use of Risk Evaluation and Mitigation Strategies to delay generic entry, Boston researchers urge Congress to revisit an “unintended consequence” created by the 2007 FDA Amendments Act.